D.A. Davidson & CO. Has $1.56 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

D.A. Davidson & CO. lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 86,511 shares of the company’s stock after acquiring an additional 5,257 shares during the period. D.A. Davidson & CO.’s holdings in Teva Pharmaceutical Industries were worth $1,559,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in TEVA. UMB Bank n.a. lifted its stake in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co lifted its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Beach Investment Counsel Inc. PA bought a new position in Teva Pharmaceutical Industries in the second quarter valued at about $48,000. Finally, Byrne Asset Management LLC acquired a new position in Teva Pharmaceutical Industries during the second quarter worth about $52,000. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Trading Up 1.3 %

Shares of TEVA opened at $16.78 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The business has a 50-day moving average of $17.56 and a 200 day moving average of $17.35. The firm has a market cap of $19.01 billion, a P/E ratio of -19.74, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.